These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38049334)

  • 21. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
    Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
    Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
    [No Abstract]   [Full Text] [Related]  

  • 23. Chimeric Antigen Receptor T Cell Therapy followed by Unrelated Cord Blood Transplantation for the Treatment of Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia in Children and Young Adults: Superior Survival but Relatively High Post-Transplantation Relapse.
    Sun G; Tang B; Wan X; Yao W; Song K; Tu M; Geng L; Qiang P; Wu Y; Zhu L; Wu Y; Liu H; Zhu X; Sun Z
    Transplant Cell Ther; 2022 Feb; 28(2):71.e1-71.e8. PubMed ID: 34839013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma.
    Hunter BD; Chen YB; Jacobson CA
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):687-705. PubMed ID: 31229163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
    Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose.
    Luque-Paz D; Sesques P; Wallet F; Bachy E; Ader F
    Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1155-1162. PubMed ID: 35838042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Infectious complications following chimeric antigen receptor T-cell therapy for a hematologic malignancy within 28 days].
    Li YN; Du MY; Li CG; Zhang YQ; Luo WJ; Kou HM; Mei H; Hu Y
    Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):739-746. PubMed ID: 34753228
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma.
    Jain T; Sauter CS; Shah GL; Maloy MA; Chan J; Scordo M; Avecilla ST; Batlevi Y; Dahi PB; Batlevi CW; Lia Palomba M; Giralt SA; Perales MA
    Leukemia; 2019 Oct; 33(10):2540-2544. PubMed ID: 31114023
    [No Abstract]   [Full Text] [Related]  

  • 29. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
    Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study.
    Wang S; Liu A; Wang N; Wang Y; Zhang A; Wang L; Yu W; Li C; Zhang Y; Hu Q
    Front Pediatr; 2022; 10():1100404. PubMed ID: 36727001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses.
    Meir J; Abid MA; Abid MB
    Transplant Cell Ther; 2021 Dec; 27(12):973-987. PubMed ID: 34587552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
    Asghar N; Masood A; Dhaliwal A; Khurana S; Davis J; Hashmi H; Husnain M
    Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):15-21. PubMed ID: 36328891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies.
    Zhu F; Wei G; Zhang M; Zhao H; Wu W; Yang L; Hu Y; Huang H
    Cell Transplant; 2020; 29():963689720919434. PubMed ID: 32314613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma.
    Ganatra S; Redd R; Hayek SS; Parikh R; Azam T; Yanik GA; Spendley L; Nikiforow S; Jacobson C; Nohria A
    Circulation; 2020 Oct; 142(17):1687-1690. PubMed ID: 33104402
    [No Abstract]   [Full Text] [Related]  

  • 35. Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.
    Wang CM; Wu ZQ; Wang Y; Guo YL; Dai HR; Wang XH; Li X; Zhang YJ; Zhang WY; Chen MX; Zhang Y; Feng KC; Liu Y; Li SX; Yang QM; Han WD
    Clin Cancer Res; 2017 Mar; 23(5):1156-1166. PubMed ID: 27582488
    [No Abstract]   [Full Text] [Related]  

  • 36. Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology.
    Khawaja F; Papanicolaou G; Dadwal S; Pergam SA; Wingard JR; Boghdadly ZE; Abidi MZ; Waghmare A; Shahid Z; Michaels L; Hill JA; Kamboj M; Boeckh M; Auletta JJ; Chemaly RF
    Transplant Cell Ther; 2023 Jan; 29(1):10-18. PubMed ID: 36273782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma.
    Xu H; Lv Q; Huang L; Cao W; Wang J; Meng F; Li C; Zheng M; Chen L; Mu K; Cheng J; Zhu L; Zhou J; Zhang Y; Wang N; Cao Y
    Cytotherapy; 2023 Feb; 25(2):185-191. PubMed ID: 36283943
    [No Abstract]   [Full Text] [Related]  

  • 38. Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma.
    Sigmund AM; Denlinger N; Huang Y; Bond D; Voorhees T; Bajwa A; Elder P; Brammer JE; Saad A; Penza S; Vasu S; de Lima M; Jaglowski S; Kittai AS
    Transplant Cell Ther; 2022 Jun; 28(6):342.e1-342.e5. PubMed ID: 35248778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.